Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine
Pediatrics 117(3): 965-978
2005
ISSN/ISBN: 1098-4275
PMID: 16382131
DOI: 10.1542/peds.2005-3038
Accession: 012448496
The purpose of this statement is to provide the rationale and recommendations for adolescent use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines. Despite universal immunization of children with multiple doses of pediatric diphtheria and tetanus toxoids and acellular pertussis ( DTaP) vaccine, pertussis remains endemic with a steady increase in the number of reported cases.
PDF emailed within 0-6 h: $19.90
Related References
Brady, M.T.; Byington, C.L.; Davies, H.D.; Edwards, K.M.; Glode, M.P.; Jackson, M.A.; Keyserling, H.L.; Maldonado, Y.A.; Murray, D.L.; Orenstein, W.A.; Schutze, G.E.; Willoughby, R.E.; Zaoutis, T.E.; Fischer, M.A.; Gellin, B.; Gorman, R.L.; Lee, L.; Pratt, R.D.; Read, J.S.; Robinson, J.; Seward, J.; Starke, J.R.; Swanson, J.; Tan, T.Q.; Baker, C.J.; Bernstein, H.H.; Kimberlin, D.W.; Long, S.S.; Meissner, H.C.; Pickering, L.K.; Rubin, L.G.; Frantz, J. 2011: Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap) Pediatrics 128(4): 809-8122011: Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010 MMWR. Morbidity and mortality weekly report 60(1): 13-15
Kamiya, H.; Cho, B-Hyun.; Messonnier, M.L.; Clark, T.A.; Liang, J.L. 2016: Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States Vaccine 34(15): 1832-1838
2013: Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012 Mmwr. Morbidity and Mortality Weekly Report 62(7): 131-135
Broder, K.R.; Cortese, M.M.; Iskander, J.K.; Kretsinger, K.; Slade, B.A.; Brown, K.H.; Mijalski, C.M.; Tiwari, T.; Weston, E.J.; Cohn, A.C.; Srivastava, P.U.; Moran, J.S.; Schwartz, B.; Murphy, T.V. 2006: Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP) Mmwr. Recommendations and Reports: Morbidity and Mortality Weekly Report. Recommendations and Reports 55(Rr-3): 1-34
Halperin, S.A.; McNeil, S.; Langley, J.; Blatter, M.; Dionne, M.; Embree, J.; Johnson, R.; Latiolais, T.; Meekison, W.; Noya, F.; Senders, S.; Zickler, P.; Johnson, D.R. 2011: Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose Vaccine 29(46): 8459-8465
2012: Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012 MMWR. Morbidity and mortality weekly report 61(25): 468-470
Fortner, K.B.; Edwards, K.M.; Broder, K.R.; Jimenez, N.; Zhu, Y.; Walter, E.B.; Heine, R.P.; Moro, P.; Liang, J.L.; Swamy, G.K. 2016: Reactogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women American Journal of Obstetrics and Gynecology 214(1): S193-S194
Kretsinger, K.; Broder, K.R.; Cortese, M.M.; Joyce, M.Patricia.; Ortega-Sanchez, I.; Lee, G.M.; Tiwari, T.; Cohn, A.C.; Slade, B.A.; Iskander, J.K.; Mijalski, C.M.; Brown, K.H.; Murphy, T.V. 2006: Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel Mmwr. Recommendations and Reports: Morbidity and Mortality Weekly Report. Recommendations and Reports 55(Rr-17): 1-37
Fortner, K.B.; Swamy, G.K.; Broder, K.R.; Jimenez-Truque, N.; Zhu, Y.; Moro, P.L.; Liang, J.; Walter, E.B.; Heine, R.P.; Moody, M.A.; Yoder, S.; Edwards, K.M. 2018: Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women Vaccine 36(42): 6354-6360
Hanson, M.P.; Kwan-Gett, T.S.; Baer, A.; Rietberg, K.; Ohrt, M.; Duchin, J.S. 2011: Infant pertussis epidemiology and implications for tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination: King County, Washington, 2002 through 2007 Archives of Pediatrics and Adolescent Medicine 165(7): 647-652
Ding, Y.; Yeh, S.H.; Mink, C.A.M.; Zangwill, K.M.; Allred, N.J.; Hay, J.W. 2013: Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) Vaccine 31(22): 2558-2564
Park, H.-J.; Kim, S.J.; Song, R.; Chen, J.; Kim, J.-H.; Devadiga, R.; Kang, H.-C. 2019: A 6-year Prospective, Observational, Multi-Center Post-Marketing Surveillance of the Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Korea Journal of Korean Medical Science 34(12): E105
Moro, P.L.; Cragan, J.; Tepper, N.; Zheteyeva, Y.; Museru, O.; Lewis, P.; Broder, K. 2016: Enhanced surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015 Vaccine 34(20): 2349-2353
Jackson, M.L.; Yu, O.; Nelson, J.C.; Nordin, J.D.; Tartof, S.Y.; Klein, N.P.; Donahue, J.G.; Irving, S.A.; Glanz, J.M.; McNeil, M.M.; Jackson, L.A. 2018: Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents Pharmacoepidemiology and Drug Safety 27(8): 921-925
New, S.; Winter, K.; Boyte, R.; Harriman, K.; Gutman, A.; Christiansen, A.; Royce, S. 2018: Barriers to Receipt of Prenatal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Among Mothers of Infants Aged <4 Months with Pertussis - California, 2016 MMWR. Morbidity and Mortality Weekly Report 67(38): 1068-1071
Terranella, A.; Rea, V.; Griffith, M.; Manning, S.; Sears, S.; Farmer, A.; Martin, S.; Patel, M. 2016: Vaccine effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during a pertussis outbreak in Maine Vaccine 34(22): 2496-2500
Moro, P.L.; Yue, X.; Lewis, P.; Haber, P.; Broder, K. 2011: Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010 Vaccine 29(50): 9404-9408
Havers, F.P.; Cho, B.-H.; Walker, J.W.; Hariri, S. 2020: Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States Vaccine 38(2): 380-387
Skoff, T.H.; Martin, S.W. 2016: Impact of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccinations on Reported Pertussis Cases Among Those 11 to 18 Years of Age in an Era of Waning Pertussis Immunity: A Follow-up Analysis JAMA pediatrics 170(5): 453-458